Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.09 USD
Change Today +0.18 / 1.65%
Volume 1.8M
NKTR On Other Exchanges
As of 5:20 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/2/14 - $17.53
52 Week Low
04/15/14 - $10.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEKTAR THERAPEUTICS (NKTR)

nektar therapeutics (NKTR) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (NKTR) Details

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, as well as MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation. The company’s drug candidates in clinical development stage also include etirinotecan pegol, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as has completed Phase II clinical trial stage for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat gastrointestinal-related solid tumors, which has completed Phase I clinical trial. Nektar Therapeutics has collaboration with Baxter Healthcare; Bayer Healthcare LLC; and AstraZeneca AB. In addition, it has license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Halozyme Therapeutics, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche); and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

438 Employees
Last Reported Date: 02/26/15
Founded in 1990

nektar therapeutics (NKTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $831.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $524.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $504.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $459.7K
Compensation as of Fiscal Year 2013.

nektar therapeutics (NKTR) Key Developments

Nektar Therapeutics - Special Call

To review the topline results from the Phase 3 BEACON study for etirinotecan pegol (NKTR-102)

Nektar Therapeutics Announces Results from its Phase 3 BEACON Study

Nektar Therapeutics announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer. BEACON compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician's choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease. In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC). Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance. NKTR-102 was designed to be the first topoisomerase I inhibitor with a novel molecular structure that concentrates the drug in vascularized tumors and extends its circulation time in the plasma. In 2012, the FDA designated NKTR-102 as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with ATC.

Nektar Therapeutics Announces Start of Phase 3 Summit-07 Study of NKTR-181 in Patients with Chronic Low Back Pain

Nektar Therapeutics announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181. This slow rate of entry is designed to reduce the euphoria that can lead to the abuse of current opioid analgesics.1 SUMMIT-07 will evaluate the efficacy, safety and tolerability of NKTR-181 in patients with chronic low back pain who are also opioid-naïve (new to treatment). NKTR-181 is a new chemical entity (NCE) that was created using Nektar's proprietary small molecule polymer conjugate technology. NKTR-181 has several potential differentiating properties that are inherent to the structure of the molecule, including a slow rate of entry into the CNS as measured by pupillometry (contraction of the pupils) and a plasma pharmacokinetic profile that supports twice-daily oral dosing. NKTR-181 is not a reformulation of a marketed opioid, which is a commonly-used method to attempt to prevent the manipulation of existing long-acting opioid drugs into more abusable forms. NKTR-181 has been granted has been granted Fast Track designation for the treatment of moderate to severe chronic pain by the U.S. Food and Drug Administration. The SUMMIT-07 Phase 3 trial utilizes an enriched-enrollment, randomized withdrawal (EERW) design and will enroll opioid-naïve patients ages 18 to 75 years who have had moderate to severe non-neuropathic chronic low back pain for at least six months. The study includes an open-label, dose titration period followed by a randomized, double-blind, placebo-controlled 12 week treatment period. During the open-label titration phase, study participants will be titrated on NKTR-181 tablets administered orally twice daily until they experience an adequate and sustained pain response. Patients who achieve this will then be randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo during the double-blind 12 week treatment period. A total of 208 patients will be randomized to each arm. No background NSAIDs are allowed throughout the study. The primary endpoint of the study is a change in pain as measured by the change in a patient's weekly pain score from baseline to week 12 of the randomized, double-blind treatment period. The SUMMIT Phase 3 program will also include a Phase 3 efficacy and safety trial in patients who are opioid-experienced (SUMMIT-12) as well as a 52-week long-term safety study (SUMMIT-LTS).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.09 USD +0.18

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $22.67 USD +0.80
Emergent Biosolutions Inc $28.52 USD +0.67
Ironwood Pharmaceuticals Inc $15.67 USD +0.23
Sucampo Pharmaceuticals Inc $14.50 USD +0.50
Theravance Inc $16.46 USD -0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation NKTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 39.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at